反应详情

Step N (1): (2R,3S)-1-((1S,3R)-3-(allyloxy)-6-methoxy-2,3-dihydro-1H-inden-1-ylamino)-3-amino-4-(3,5-difluorophenyl)butan-2-ol (20 mg, 0.05 mmol) from step E (2), (S)-2-((S)-3-acetamido-3-sec-butyl-2-oxopyrrolidin-1-yl)pent-4-enoic acid (14 mg, 0.048 mmol) from step L (7), EDC (10 mg, 0.05 mmol), HOBt (7 mg, 0.05 mmol), DIEA (40 μL, 0.24 mmol) were mixed in 2 mL of DMF. The mixture was stirred at RT for 24 h. Purified with reverse phase Prep-HPLC to give 14.1 mg of (S)-2-((S)-3-acetamido-3-sec-butyl-2-oxopyrrolidin-1-yl)-N-((2S,3R)-4-((1S,3R)-3-(allyloxy)-6-methoxy-2,3-dihydro-1H-inden-1-ylamino)-3-hydroxy-1-phenylbutan-2-yl)pent-4-enamide as a light brown viscous residue (TFA salt): LC-MS (M+H)+=661.37, 1H NMR (300 MHz, CDCl3) δ ppm 0.82 (t, J=5.86 Hz, 2H) 0.89-1.69 (m, 5H) 1.86-2.04 (m, 4H) 2.35-2.90 (m, 5H) 3.05-4.17 (m, 19H) 4.57 (d, J=6.59 Hz, 1H) 4.75 (d, J=4.76 Hz, 1H) 4.87-4.98 (m, 1H) 5.12-5.34 (m, 1H) 5.38-5.57 (m, 1H) 5.78-5.94 (m, 1H) 6.01 (s, 1H) 6.84-6.95 (m, 1H) 7.02-7.36 (m, 8H) 7.70 (d, J=9.15 Hz, 1H).

1. customPurified with reverse phase Prep-HPLC